Altium Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-65,000
| Closed | -$2.31M | – | 73 |
|
|
2023
Q4 | $2.31M | Sell |
65,000
-197,000
| -75% | -$7.01M | 1.57% | 20 |
|
|
2023
Q3 | $7.79M | Buy |
262,000
+127,000
| +94% | +$3.78M | 4.06% | 9 |
|
|
2023
Q2 | $2.43M | Buy |
135,000
+35,000
| +35% | +$631K | 1.84% | 21 |
|
|
2023
Q1 | $1.61M | Buy |
+100,000
| New | +$1.61M | 0.89% | 40 |
|
|
2022
Q2 | – | Sell |
-204,000
| Closed | -$4.48M | – | 129 |
|
|
2022
Q1 | $4.48M | Sell |
204,000
-127,000
| -38% | -$2.79M | 1.5% | 24 |
|
|
2021
Q4 | $9.4M | Buy |
331,000
+138,000
| +72% | +$3.92M | 2.59% | 5 |
|
|
2021
Q3 | $4.06M | Sell |
193,000
-340,033
| -64% | -$7.16M | 1.07% | 37 |
|
|
2021
Q2 | $10M | Buy |
533,033
+171,103
| +47% | +$3.23M | 2.33% | 4 |
|
|
2021
Q1 | $5.53M | Hold |
361,930
| – | – | 1.54% | 14 |
|
|
2020
Q4 | $5.11M | Buy |
+361,930
| New | +$5.11M | 1.91% | 11 |
|